Is the use of letrozole to induce ovulation teratogenic?

Canadian Family Physician

Volumn 54, Issue 3, 2008, Pages 353-354

  Gill, Simerpal Kaur ^a   Moretti, Myla ^a   Koren, Gideon ^a,b  

^a Motherisk Program

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; LETROZOLE;

ABSENCE OF SIDE EFFECTS; ARTICLE; BIRTH DEFECT; DRUG CONTRAINDICATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; NONHUMAN; OVULATION; PREGNANCY; PREMENOPAUSE; PRESCRIPTION; RISK; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; AROMATASE INHIBITORS; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; NITRILES; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; RISK; TRIAZOLES;

EID: 40949105582     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005;192(2):381-6.
2. Fisher SA, Reid RL, Van Vugt DA, Casper RF. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 2002;78(2):280-5.
3. Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil Steril 2005;84(Suppl 1):S95.
4. Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006;85(6):1761-5. Epub 2006 May 20.
5. Forman R, Gill S, Moretti M, Tulandi T, Koren G, Casper R. Fetal safety of letrozole and clomiphene citrate for ovulation induction. J Obstet Gynaecol Can 2007;29(8):668-71.
6. Dziadek M. Preovulatory administration of clomiphene citrate to mice causes fetal growth retardation and neural tube defects (exencephaly) by an indirect maternal effect. Teratol 1993;47(4):263-73.
7. US Food and Drug Administration, Center for Drug Evaluation and Research. FDA oncology tools product label details for administration of letrozole. Rockville, MD: US Food and Drug Administration; 2003. Available from: www.accessdata.fda.gov/scripts/cder/onctools/administer.cfm?GN= letrozole. Accessed 2008 Feb 15.
8. Heitland G, Hurlbut KM, editors. REPROTOX® database [electronic version]. Greenwood Village, CO: Micromedex® Healthcare Series. Available from: www.thomsonhc.com.myaccess.library.utoronto.ca. Accessed 2008 Feb 1.